138 related articles for article (PubMed ID: 21384094)
1. Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: a prospective study.
Fourie CM; Van Rooyen JM; Kruger A; Olsen MH; Eugen-Olsen J; Schutte R; Schutte AE
Inflammation; 2012 Feb; 35(1):221-9. PubMed ID: 21384094
[TBL] [Abstract][Full Text] [Related]
2. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB
J Med Virol; 2008 Feb; 80(2):209-16. PubMed ID: 18098145
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.
Ostrowski SR; Katzenstein TL; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2006 Jun; 63(6):478-86. PubMed ID: 16764702
[TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years.
Botha S; Fourie CM; Schutte R; Eugen-Olsen J; Schutte AE
Hypertens Res; 2015 Jun; 38(6):439-44. PubMed ID: 25740290
[TBL] [Abstract][Full Text] [Related]
5. suPAR associates to glucose metabolic aberration during glucose stimulation in HIV-infected patients on HAART.
Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB
J Infect; 2008 Jul; 57(1):55-63. PubMed ID: 18328568
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expression.
Nebuloni M; Zawada L; Ferri A; Tosoni A; Zerbi P; Resnati M; Poli G; Genovese L; Alfano M
PLoS One; 2013; 8(7):e70606. PubMed ID: 23923008
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.
Botha S; Fourie CMT; Schutte R; Eugen-Olsen J; Pretorius R; Schutte AE
Int J Cardiol; 2015 Apr; 184():631-636. PubMed ID: 25771228
[TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients.
Ostrowski SR; Katzenstein TL; Piironen T; Gerstoft J; Pedersen BK; Ullum H
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):337-42. PubMed ID: 15097149
[TBL] [Abstract][Full Text] [Related]
9. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.
Rasmussen LJ; Knudsen A; Katzenstein TL; Gerstoft J; Obel N; Jørgensen NR; Kronborg G; Benfield T; Kjaer A; Eugen-Olsen J; Lebech AM
HIV Med; 2016 May; 17(5):350-7. PubMed ID: 26365671
[TBL] [Abstract][Full Text] [Related]
10. Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study.
Schutte AE; Myburgh A; Olsen MH; Eugen-Olsen J; Schutte R
Thromb Res; 2012 Aug; 130(2):273-7. PubMed ID: 22113150
[TBL] [Abstract][Full Text] [Related]
11. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.
Sidenius N; Sier CF; Ullum H; Pedersen BK; Lepri AC; Blasi F; Eugen-Olsen J
Blood; 2000 Dec; 96(13):4091-5. PubMed ID: 11110678
[TBL] [Abstract][Full Text] [Related]
12. Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort study.
Langkilde A; Petersen J; Klausen HH; Henriksen JH; Eugen-Olsen J; Andersen O
PLoS One; 2012; 7(12):e51698. PubMed ID: 23251607
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa.
Lawn SD; Myer L; Bangani N; Vogt M; Wood R
BMC Infect Dis; 2007 May; 7():41. PubMed ID: 17509133
[TBL] [Abstract][Full Text] [Related]
14. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms.
Schneider UV; Nielsen RL; Pedersen C; Eugen-Olsen J
BMC Infect Dis; 2007 Nov; 7():134. PubMed ID: 18021410
[TBL] [Abstract][Full Text] [Related]
16. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.
Zimmermann HW; Reuken PA; Koch A; Bartneck M; Adams DH; Trautwein C; Stallmach A; Tacke F; Bruns T
J Intern Med; 2013 Jul; 274(1):86-100. PubMed ID: 23432143
[TBL] [Abstract][Full Text] [Related]
17. Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression.
Hoenigl M; Moser CB; Funderburg N; Bosch R; Kantor A; Zhang Y; Eugen-Olsen J; Finkelman M; Reiser J; Landay A; Moisi D; Lederman MM; Gianella S;
Clin Infect Dis; 2019 Aug; 69(4):676-686. PubMed ID: 30418519
[TBL] [Abstract][Full Text] [Related]
18. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
Persson M; Engström G; Björkbacka H; Hedblad B
Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
[TBL] [Abstract][Full Text] [Related]
19. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
Jhee JH; Nam BY; Lee CJ; Park JT; Han SH; Kang SW; Park S; Yoo TH
J Am Heart Assoc; 2021 Jan; 10(1):e017225. PubMed ID: 33325248
[TBL] [Abstract][Full Text] [Related]
20. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
Cinque P; Nebuloni M; Santovito ML; Price RW; Gisslen M; Hagberg L; Bestetti A; Vago G; Lazzarin A; Blasi F; Sidenius N
Ann Neurol; 2004 May; 55(5):687-94. PubMed ID: 15122709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
